Capital Research Global Investors
AMED

Capital Research Global Investors’s Amedisys AMED Stock Holding History

Capital Research Global Investors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-249,566
Closed -$24.2M – 438
2022
Q3 		$24.2M Sell
249,566
-297,500
-54% -$35.5M 0.01% 353
2022
Q2 		$57.5M Hold
547,066
– – 0.02% 315
2022
Q1 		$94.3M Buy
547,066
+41,446
+8% +$6.19M 0.02% 311
2021
Q4 		$81.8M Buy
505,620
+98,766
+24% +$15.9M 0.02% 335
2021
Q3 		$60.7M Buy
406,854
+389,654
+2,265% +$81M 0.01% 356
2021
Q2 		$4.21M Hold
17,200
– – ﹤0.01% 426
2021
Q1 		$4.55M Hold
17,200
– – ﹤0.01% 413
2020
Q4 		$5.04M Hold
17,200
– – ﹤0.01% 389
2020
Q3 		$4.07M Hold
17,200
– – ﹤0.01% 389
2020
Q2 		$3.42M Buy
+17,200
New +$3.21M ﹤0.01% 388

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital Research Global Investors's AMED Position: Q4 2022 in Review

Capital Research Global Investors sold out of Amedisys (AMED) in Q4 2022, closing a stake of 249,566 shares — an estimated $24.2M sold.

Capital Research Global Investors first reported a position in AMED in Q2 2020 and held it in 10 quarters. The position peaked at $94.3M in Q1 2022. 278 funds tracked by Wall St. Rank hold AMED as of Q4 2022.

  • Capital Research Global Investors reported no remaining Amedisys position as of Q4 2022 after selling out during the quarter.
  • Capital Research Global Investors sold 249,566 Amedisys shares in Q4 2022, an estimated $24.2M.
  • Capital Research Global Investors first reported a position in Amedisys in Q2 2020 and held it in 10 quarters.
  • Capital Research Global Investors's Amedisys position peaked at $94.3M in Q1 2022.
  • 278 funds tracked by Wall St. Rank held Amedisys as of Q4 2022.

Based on Capital Research Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.